TSRL CEO to present microneedle drug delivery research at PharmaEd Forum 2026

TSRL President and CEO Dr. Elke Lipka will present new hydrogel microneedle patch research at the PharmaEd Microneedle & Transdermal Delivery Forum in Providence, Rhode Island, on Aug. 27-28. The work centers on TSR-825, a trospium chloride patch aimed at improving overactive bladder treatment by sustaining drug levels and reducing side effects.

Why it matters: - TSRL is pushing a skin-based drug delivery approach that could improve how established medicines are administered. - The research targets overactive bladder, where oral treatment can be limited by inconsistent absorption and dose-related side effects. - The company is also expanding the same hydrogel microneedle platform across other therapeutic areas.

What happened: - TSRL announced that President and CEO Dr. Elke Lipka will present at the PharmaEd Microneedle & Transdermal Delivery Forum 2026. - The conference will take place Aug. 27-28 in Providence, Rhode Island. - The forum brings together researchers from industry, academia and regulatory organizations focused on microneedle and transdermal drug delivery. - Lipka's talk is titled, "Optimization of Trospium Chloride Delivery via Hydrogel Microprojection Array Patches (MAP): Impact of Device Architecture and Reservoir Design." - The presentation will focus on TSRL's hydrogel-forming microneedle array technology and its potential to improve treatment for patients with overactive bladder.

The details: - The presentation will highlight TSR-825, TSRL's MAP formulation of trospium chloride. - Trospium chloride is a clinically established therapy. - The company says oral use can be limited by inconsistent bioavailability and dose-related adverse events. - TSRL says systematic evaluation of array architecture and reservoir design produced sustained plasma drug concentrations over an anticipated seven-day period in preclinical studies. - TSRL says the same work minimized peak drug exposure. - The hydrogel MAP platform is designed as a self-administered, painless drug delivery system. - The platform builds on TSRL's lead program, TSR-066, for seasonal influenza. - TSRL is evaluating the platform through formulation screening, in vitro permeation studies, skin irritation assessments and in vivo validation. - TSRL said the presentation will also address the broader potential of the platform across additional therapeutic applications.

Between the lines: - The company is trying to turn a delivery mechanism into a differentiator, not just the drug payload itself. - If the preclinical results translate, the platform could support better tolerability and adherence for patients who struggle with oral dosing. - A conference presentation also signals TSRL's effort to build visibility with drug delivery specialists, regulators and potential collaborators. - TSRL said its participation follows continued momentum for its drug delivery programs, including ongoing NIH-supported research on hydrogel-based MAP technologies.

What's next: - Lipka will present the research at the forum later this month. - TSRL will continue evaluating the hydrogel MAP platform across multiple therapeutic applications. - The company also plans to keep advancing its NIH-supported MAP research. - More information is available in the company's announcement.